Coronavirus: Testing boss ‘very sorry’ for shortages

Some people are being asked to travel hundreds of miles for tests as labs struggle to keep up.

Share Button

Health24.com | Smartwatch EKGs quickly deliver crucial heart data

  • EKG readings from a smartwatch were found to be nearly as accurate as standard EKGs
  • EKGs are critical to establish if a patient with chest pain has had a heart attack
  • Smartwatch EKGs could speed up diagnosis and treatment when time is of the essence

Could a smartwatch app save a heart attack patient’s life? Quite possibly, according to Italian researchers.

They found that electrocardiograph (EKG) readings from a smartwatch were nearly as accurate as standard EKGs among patients with suspected heart attacks.

“A [standard] electrocardiograph is not always readily available,” said study author Dr Ciro Indolfi. “[So] the ability to identify an ongoing heart attack quickly and easily thanks to the use of a simple smartphone could be of great help in certain situations in reducing the negative consequences of a heart attack.”

Indolfi is director of cardiovascular research at Magna Graecia University in Catanzaro, Italy.

FDA-approved for atrial fibrillation

An EKG is a graphic representation of the heart’s electrical activity. Indolfi noted that these readouts are critical for establishing whether a patient with chest pain has had a heart attack. It can also quickly identify specific causes.

To see whether smartphone electrocardiograms actually work, researchers assessed EKG reliability among 81 patients who sought care for a likely heart attack at one clinic between April 2019 and January 2020. Two-thirds were men (average age: 61).

All received a standard “12-lead” EKG, which uses 12 electrodes at different spots on the chest and limbs to produce a reading.

Patients also had an EKG using the Apple Watch Series 4. The US Food and Drug Administration (FDA) has approved the smartwatch’s built-in EKG tool as a reliable way to detect the serious heartbeat irregularity known as atrial fibrillation.

Instead of 12 electrode leads, the smartwatch is equipped with sensors designed to form a single electrode lead. As a workaround, researchers successively placed the watch in nine spots on each patient’s body to generate multiple readings. The readings were then uploaded to an Apple iPhone.

Watch doesn’t generate diagnosis

For comparison purposes, 19 men and women who were not suspected of having experienced a heart attack also had standard and smartwatch EKGs.

Watch-generated EKGs were 94% accurate when it came to correctly identifying and distinguishing between various types of heart attacks, according to Indolfi. The watch also correctly noted that no heart attack had taken place in more than nine out of 10 healthy patients.

The watch does not generate a diagnosis; the EKG readings need to be interpreted by a doctor. But the findings suggest that “with the Apple Watch it is possible to perform a nine-lead EKG with an almost similar reliability as the standard EKG,” Indolfi said.

That’s important, he added, because the faster post-heart attack treatments are administered, the better the outcome. That’s especially true, Indolfi said, among patients who experience a very severe form of heart attack known as a STEMI (ST-segment elevation myocardial infarction).

Such patients can do well after insertion of a stent or a balloon (coronary angioplasty) to widen a blocked artery, Indolfi noted. But that procedure only “reduces mortality if it is performed promptly”, meaning administering an EKG within 10 minutes and then, treatment within two hours.

Faster diagnosis and treatment

Dr Gregg Fonarow, director of the Ahmanson-University of California, Los Angeles Cardiomyopathy Center, welcomed the findings with cautious optimism.

“This new feasibility study shows that a smartwatch could be used to obtain multiple leads of an EKG,” he said, underscoring the “high level [of] agreement” between smartwatch and standard readings.

Fonarow said more follow-up work will be needed to confirm the findings.

But he agreed that smartwatch EKGs could ultimately prove very helpful in speeding up diagnosis and treatment in situations where time is of the essence, including heart attacks in setting where standard EKGs are not available.

The findings were published in the online edition of JAMA Cardiology.

Image credit: Shutterstock

NEXT ON HEALTH24X

Share Button

Health24.com | Mom-to-be’s flu shot doesn’t raise autism risk

  • Many studies have shown that flu shots during pregnancy are safe and won’t increase the risk of autism in babies
  • Getting the flu is riskier than a flu vaccination
  • A flu shot may also reduce the burden on healthcare systems, freeing up resources during a possible Covid-19 resurgence

Pregnant women are understandably worried about everything that goes into their bodies. But here’s one worry they can cross off that list: flu shots.

A large, new study has confirmed that an expectant woman’s flu shot doesn’t increase the risk of autism in her child. And that’s true even if the vaccine is given during the first trimester of pregnancy, the Swedish study found.

“The flu vaccine is safe during pregnancy. This study, as well as many others, have consistently shown that flu vaccine is safe,” noted vaccine expert Dr Paul Offit. He’s director of the Vaccine Education Center at Children’s Hospital of Philadelphia, and was not involved in the current research.

Developmental disorders

What can put mom and baby at risk is getting the flu.

“Pregnant women have a sevenfold increase of being hospitalised with pneumonia if they get the flu,” Offit said. And women who get the flu during pregnancy also have an increased risk of delivering their baby early, according to the American College of Obstetricians and Gynecologists.

Autism spectrum disorders are developmental disorders that affect communication and behaviour. Children with autism have varying degrees of impaired communication and social skills and they may engage in repetitive behaviours, the researchers said. These disorders are thought to stem from both hereditary and environmental factors.

The researchers – led by Dr Jonas Ludvigsson from the Karolinska Institute in Stockholm – used data from national Swedish health registers. They looked at information on babies born between October 2009 and September 2010.

During that time, nearly 40 000 infants were born to women who received a flu vaccine. The vaccine was specifically for the H1N1 (swine flu) strain. The children were compared to more than 29 000 infants whose mothers didn’t get a vaccine.

Flu vaccines safe in pregnancy

After a follow-up of almost seven years, the researchers saw no significant difference in the rates of autism spectrum disorders among the children. Results were similar for flu vaccines given in the first trimester of pregnancy.

Ludvigsson said that research like this is even more critical right now. “Anticipating a vaccine against Covid-19, millions of pregnant women are likely to be offered such a vaccination. While our research group did not study Covid-19 vaccine effects, our research on H1N1 vaccination adds to the current knowledge about vaccines, pregnancy and offspring disease in general,” he said in an institute statement.

The new study was published in the Annals of Internal Medicine. Funding was provided by the Swedish Research Council and the Swedish Council for Working Life and Social Research.

Anders Hviid, a professor of pharmacoepidemiology from the Statens Serum Institut and University of Copenhagen in Denmark, said, “The current evidence supports that flu vaccines are safe to use in pregnancy and that they provide protection against a potentially serious infectious disease for both mother and child.” He wrote an editorial accompanying the study.

“This year, a flu shot will not only provide protection during pregnancy for mother and child and protection in early infancy due to transfer of maternal antibodies, but may also reduce the burden on our healthcare systems freeing up resources, if needed, during a possible autumn and winter Covid-19 resurgence,” said Hviid.

Concerned and vigilant

He added that because of the potential benefits, it’s “somewhat disheartening that influenza vaccination in pregnancy is not embraced to a greater degree”.

Hviid said it’s understandable to be concerned and vigilant during pregnancy. “I hope that the many studies supporting the safety of vaccines and their benefits can help overcome any reservations,” he said.

Offit agreed that with the Covid-19 pandemic, it’s even more important to get a flu vaccine.

“To protect themselves and their unborn child, pregnant women should get the flu shot,” Offit advised, adding, “And get it as soon as possible.”

Image credit: iStock

Share Button

Coronavirus: ‘Add upset stomach in children to symptoms’

Researchers say it may be worth adding diarrhoea and vomiting to the list of symptoms.

Share Button

Treat acne-prone skin with care

Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.

Advertising & Sponsorship

Mayo Clinic Marketplace

Check out these best-sellers and special offers on books and newsletters from Mayo Clinic.

Share Button

Coronavirus: Facebook, Twitter and YouTube ‘fail to tackle anti-vaccination posts’

Campaigners claim Facebook, Twitter and YouTube failed to act on flagged ‘clearly harmful posts’.

Share Button

Rise in gonorrhoea cases in England prompts safe sex warning

Annual STI cases are up by 5%, with 70,936 new gonorrhoea diagnoses driving the increase.

Share Button

Plasmin could be the link between COVID-19 comorbidities and serious illness

Sadis Matalon, Ph.D., of the University of Alabama at Birmingham and colleagues in Texas and San Francisco asked that question in a hypothesis paper published online in Physiological Reviews. This study was made available online in March 2020 ahead of final publication in issue on July 1, 2020. They reviewed, in detail, research literature for comorbidities like hypertension, diabetes, coronary heart disease, cerebrovascular illness, chronic obstructive pulmonary disease and kidney dysfunction, as well as many viral studies, studies of COVID-19 pathology and clinical presentation, and literature on the life-threatening acute respiratory distress syndrome.

Twelve days later, UAB Professor Emeritus Timothy Ness, M.D., Ph.D., posted plans on ClinicalTrials.gov for an exploratory COVID-19 outpatient study to test Matalon’s hypothesis and prevent worse clinical outcomes.

In the Physiological Reviews paper, the researchers noted that all those comorbidities feature elevated levels of the extracellular protease plasmin. Plasmin is able to nick proteins at amino acid sequences called furin sites. For many viruses, this nicking at furin sites increases their infectivity. Both SARS and MERS — the two virulent coronaviruses that are related to the COVID-19 virus — “have evolved an unusual two-step furin activation for fusion, suggestive of a role during the process of emergence into the human population,” the researchers wrote.

They noted that the COVID-19 virus, SARS-CoV-2, also has a furin site on its spike protein, the vital, viral protein for viral attachment to a lung cell. The researchers proposed that plasmin may cleave that furin site in the spike protein to increase its infectivity and virulence, and they hypothesized that, “the plasmin system may prove a promising therapeutic target for combating COVID-19.”

Ness already knew there is an inexpensive, commonly used drug — tranexamic acid, or TXA — that targets plasmin by inhibiting its conversion from the inactive precursor, plasminogen, to the active protease, plasmin.

TXA is approved by the U.S. Food and Drug Administration for treatment of heavy menstrual bleeding because having lower plasmin levels allows better clotting. TXA has a long track record of safety and is commonly given off-label. At UAB Hospital, TXA is used perioperatively as a standard-of-care for orthopedic and cardiac bypass surgeries; it is commonly used for hemorrhaging trauma patients and also has been used for spinal surgery, neurosurgery and corrective jaw surgeries. It is currently being studied for perioperative use in Cesarean section surgeries.

For the clinical trial, Ness and colleagues have started a double-blind study, giving either TXA or a placebo pill to COVID-19 outpatients who were recently diagnosed with COVID-19. Patients also receive an anticoagulant. The overall goal of the exploratory study is to assess both safety and efficacy of five days of TXA versus placebo in the COVID-19 population. Enrollment is ongoing.

Ness and colleagues hypothesize that the TXA treatment will reduce the infectivity and virulence of the virus, as measured by reduced need for hospitalization within a week if a patient’s condition deteriorates. Adults 19 years old and older are eligible, and all patients — whether in the control group or the TXA group — receive standard care as directed by their primary caretakers.

Other principal investigators for the trial are Sonya Heath, M.D., professor in the UAB Department of Medicine Division of Infectious Diseases; and Brant Wagener, M.D., Ph.D., associate professor, and Sadis Matalon, Ph.D., distinguished professor, both in the UAB Department of Anesthesiology and Perioperative Medicine. Ness is professor emeritus in that department.

Authors of the Physiological Reviews paper, “Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility,” are Hong-Long Ji and Runzhen Zhao, University of Texas Health Science Centre at Tyler; Michael A. Matthay, University of California, San Francisco; and Matalon.

Share Button

An unprecedented discovery of cell fusion

Like humans, bacteria live together in communities, sometimes lending a hand — or in the case of bacteria, a metabolite or two — to help their neighbors thrive. Understanding how bacteria interact is critical to solving growing problems such as antibiotic resistance, in which infectious bacteria form defenses to thwart the medicines used to fight them.

Now, researchers at the University of Delaware have discovered that bacteria do more than just work together. Bacterial cells from different species can combine into unique hybrid cells by fusing their cell walls and membranes and sharing cellular contents, including proteins and ribonucleic acid (RNA), the molecules which regulate gene expression and control cell metabolism. In other words, the organisms exchange material and lose part of their own identity in the process.

This unprecedented observation, which was reported on Tuesday, Sept. 1 in mBio, a journal of the American Society for Microbiology, has the potential to shed light on unexplained phenomena affecting human health, energy research, biotechnology and more.

The research team, led by Eleftherios (Terry) Papoutsakis, Unidel Eugene Du Pont Chair of Chemical and Biomolecular Engineering, studied interactions between Clostridium ljungdahlii and C. acetobutylicum. These species of bacteria work together in a syntrophic system, producing metabolites that are mutually beneficial to each other’s survival.

The team found that C. ljungdahlii invades C. acetobutylicum. The two organisms combine cell walls and membranes and exchange proteins and RNA to form hybrid cells, some of which continue to divide and in fact differentiate into the characteristic sporulation program.

“They mix their machinery to survive or do metabolism, and that’s kind of extraordinary, because we always assumed that each and every organism has its own independent identity and machinery,” said Papoutsakis.

Previously, researchers have observed that bacteria could exchange some material through nanotubes. The combination into hybrid cells was unexpected.

“This is the first time we’ve shown this in this bacteria, and it’s also a new mechanism of how material is exchanged,” said Kamil Charubin, a doctoral student in chemical and biomolecular Engineering and first author of the paper.

Although this phenomenon of interspecies microbial fusion is now being reported for the first time, it is likely ubiquitous in nature among many bacterial pairs.

So why do bacteria bother to fuse together? The simple answer is likely because this process allows the microbes to share machinery that will increase their odds of survival.

For example, some pathogenic bacteria — those that can cause disease — may borrow proteins from other antibiotic-resistant bacteria in order to shore up their own resistance. Some bacteria might borrow machinery from others in order to evade detection by the immune system. This could also help to explain why some bacteria are difficult to culture, or grow for study or medical diagnostic purposes. These difficult-to-culture bacteria might combine with or work with and depend on other microorganisms for their existence instead of growing and multiplying on their own.

The team’s findings may influence understanding of the evolution of biology because once bacterial species share machinery, they can evolve together instead of only evolving on their own, said Papoutsakis.

“These findings will guide new thinking in not just the field of microbial evolution, but also toward biotechnological solutions that can benefit the soldier,” said Dr. Robert Kokoska, program manager, Army Research Office (ARO), an element of the U.S. Army Combat Capabilities Development Command’s Army Research Laboratory. “These include studies of how the human microbiome shapes soldier human health and cognition and how microbial communities can be better designed for a broad range of advances including strategies for reliable in-field biological sensing, waste remediation and novel means of biosynthesis.”

This work was supported by the Army Research Office (award no. W911NF-17-1-0343, and W911NF-19-1-0274) and the U.S. Department of Energy (DE-SC0019155).

Story Source:

Materials provided by University of Delaware. Original written by Julie Stewart. Note: Content may be edited for style and length.

Share Button

Study examines the benefits of virtual stroke rehabilitation programs

While virtual medical and rehabilitation appointments seemed novel when COVID-19 first appeared, they now seem to be part of the new norm and might be paving the way to the future.

A recent review paper, co-authored by Brodie Sakakibara with the Centre for Chronic Disease Prevention and Management (CCDPM) has determined that virtual appointments, in the form of telerehabilitation, also work for people recovering from a stroke.

After a stroke, a client is provided with a therapy program to help re-gain loss of skills or motion — this can range from speech and memory, strength, balance and endurance. While not initially introduced for disease outbreaks, Sakakibara a UBCO assistant professor says research shows remote therapy can be effective during stroke recovery.

“Telerehabilitation has been promoted as a more efficient means of delivering rehabilitation services to stroke patients while also providing care options to those unable to attend conventional therapy,” says paper co-author Sakakibara. “These services can be provided to remote locations through information and communication technologies and can be accessed by patients in their homes.”

To learn how effective telerehabilitation can be, six different clinical trials — examining stroke telerehabilitation programs — were launched across Canada as part of a Heart and Stroke Foundation initiative. People recovering from a stroke were provided with interventions ranging from lifestyle coaching to memory, speech skills and physical-exercise training.

“Researchers from each of the six trials came together to write a review paper describing their experiences conducting a telerehabilitation study, and to report on the facilitators and barriers to the implementation of telerehab services within a research context,” says Sakakibara.

Going forward with telerehabilitation as a new reality, Sakakibara says the study authors determined there are important lessons learned from each of the six trials. Most notably, the efficacy and cost of telerehabilitation is similar to that of traditional face-to-face management. He also notes patients mostly reported satisfaction with the telerehabilitation when therapists were trained appropriately, and when there was some social interaction. Overall, clinicians prefer face-to-face interactions but will use telerehabilitation when face-to-face is not feasible.

And finally, since seniors are a key target group for stroke rehabilitation — as stroke is associated with aging — the technology needs to be easy to use and suit the needs of the end users.

“The older adult of today, in terms of technology comfort and use, is different than the older adult of tomorrow,” he says. “While there might be some hesitation of current older adults using technology to receive health and rehab services, the older adult of tomorrow likely is very comfortable using technology. This represents a large opportunity to develop and establish the telehealth/rehabilitation model of care.”

Sakakibara notes COVID-19 has amplified the necessity for telehealth and telerehabilitation for many Canadians — especially those in remote areas or for the estimated 70 per cent of stroke victims who are no longer able to drive.

“Prior to the outbreak, telehealth/rehabilitation was highly recommended in Canadian stroke professional guidelines, but was underused,” he says. “Now in response to COVID-19, the use of telerehabilitation has been accelerated to the forefront. Once these programs are implemented in practice, it’ll be part of the norm, even when the outbreak is over. It is important that we develop and study telerehabilitation programs to ensure the programs are effective and benefit the patients.”

Share Button